4//SEC Filing
Dye Justin 4
Accession 0001104659-24-024608
CIK 0001622879other
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 6:36 PM ET
Size
20.4 KB
Accession
0001104659-24-024608
Insider Transaction Report
Form 4
Dye Justin
Director
Transactions
- Award
Common Stock
2023-12-29+123,153→ 1,739,516 total - Purchase
Series A Cumulative Convertible Preferred Stock
2023-05-15$1000.00/sh+183$183,000→ 183 total(indirect: See footnote)Exercise: $1.20→ Common Stock (183,805 underlying) - Purchase
Series A Cumulative Convertible Preferred Stock
2023-05-15$1000.00/sh+122$122,000→ 305 total(indirect: See footnote)Exercise: $1.20→ Common Stock (122,537 underlying) - Purchase
Series A Cumulative Convertible Preferred Stock
2023-05-16$1000.00/sh+140$140,000→ 445 total(indirect: See footnote)Exercise: $1.20→ Common Stock (140,616 underlying)
Holdings
- 21,350(indirect: See footnote)
Series A Cumulative Convertible Preferred Stock
Exercise: $1.20→ Common Stock (3,333,333 underlying) - 9,287,500(indirect: See footnote)
Common Stock
- 500,000(indirect: See footnote)
Common Stock
- 5,060(indirect: See footnote)
Series A Cumulative Convertible Preferred Stock
Exercise: $1.20→ Common Stock (4,216,667 underlying)
Footnotes (11)
- [F1]The issuer granted the reporting person shares of common stock with an aggregate value of $75,000 (based on the closing price of the common stock on the OTCQX Best Market on December 29, 2023) for service on the board of directors.
- [F10]Pursuant to that certain Secondary Purchase & Sale Agreement dated as of May 16, 2023 by and among Dye LLLP and those certain seller named therein, Dye LLLP agreed to purchase these certain shares of Series A Preferred Shares at a Closing occurring as of May 15, 2023.
- [F11]5,060 Series A Preferred Shares are held by Dye Capital and 21,350 Series A Preferred Shares by Dye Capital Cann Holdings II, LLC ("Cann II"). Dye Capital is the manager of Cann II. As the general partner of Dye Capital, Mr. Dye has voting and investment control over the Series A Preferred Shares held by Dye Capital and Cann II. Mr. Dye disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
- [F2]Represents shares of common stock held by Dye Capital & Company ("Dye Capital"). As the general partner of Dye Capital, Mr. Dye has voting and investment control over the securities held by Dye Capital. Mr. Dye disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
- [F3]Represents shares of common stock held by Dye Capital LLLP ("Dye LLLP"). As the managing partner of Dye LLLP, Mr. Dye has voting and investment control over the securities held by Dye LLLP. Mr. Dye disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
- [F4]Subject to adjustment, as described in the Certificate of Designation of Series A Cumulative Convertible Preferred Stock (the "Certificate of Designation") of Medicine Man Technologies, Inc. (the "Company").
- [F5]The shares of Series A Cumulative Convertible Preferred Stock (the "Series A Preferred Shares") are convertible into shares of the Company's common stock (the "Common Shares") upon the events specified in the Certificate of Designation. The Series A Preferred Shares have no expiration date.
- [F6]Represents the number of Common Shares issuable upon conversion of the Series A Preferred Shares on the date of the reported transaction. Each Series A Preferred Share shall be convertible into that number of Common Shares equal to the preference amount (initially $1,000) plus any accrued dividends with respect to such share, divided by the conversion price (initially $1.20), subject to adjustment as set forth in the Certificate of Designation. The Series A Preferred Shares earn a cumulative dividend of 8% per annum.
- [F7]Represents shares of Series A Cumulative Convertible Preferred Stock held by Dye LLLP. As the managing partner of Dye LLLP, Mr. Dye has voting and investment control over the securities held by Dye LLLP. Mr. Dye disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
- [F8]Pursuant to that certain Secondary Purchase & Sale Agreement dated as of May 15, 2023 by and among Dye LLLP and those certain seller named therein, Dye LLLP agreed to purchase these certain shares of Series A Preferred Shares at a Closing occurring as of May 15, 2023.
- [F9]Pursuant to that certain Secondary Purchase & Sale Agreement dated as of May 15, 2023 by and among Dye LLLP and those certain seller named therein, Dye LLLP agreed to purchase these certain shares of Series A Preferred Shares at a Closing occurring as of May 15, 2023.
Documents
Issuer
Medicine Man Technologies, Inc.
CIK 0001622879
Entity typeother
Related Parties
1- filerCIK 0001654539
Filing Metadata
- Form type
- 4
- Filed
- Feb 14, 7:00 PM ET
- Accepted
- Feb 15, 6:36 PM ET
- Size
- 20.4 KB